Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brazil's R&D-based industry outlines priorities for new president

This article was originally published in Scrip

Executive Summary

With Brazil's new president Dilma Rousseff to be inaugurated in January, the pharmaceutical industry has a list of issues that it would like the government to tackle. Greater price freedom and reducing the time it takes to grant a patent are just two priorities, explains Jorge Raimundo, president of the advisory council of Interfarma, Brazil's R&D-based industry association.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC011259

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel